| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | SUPPRESSION OF ITCH | US14900892 | 2014-07-09 | US20160137999A1 | 2016-05-19 | Keith FOSTER |
| The invention provides a polypeptide, for use in suppressing or treating itch, wherein the polypeptide comprises: a non-cytotoxic protease, which protease is capable of cleaving a SNARE protein in an itch-specific DRG neuron or a pruriceptor; a Targeting Moiety (TM) that is capable of binding to a Binding Site on the itch-specific DRG neuron or a pruriceptor, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the itch-specific DRG neuron or a pruriceptor, and wherein said itch-specific DRG neuron or a pruriceptor expresses said SNARE protein; and a translocation domain that is capable of translocating the protease from within an endosome, across the endosomal membrane and into the cytosol of the itch-specific DRG neuron or a pruriceptor; with the proviso that the polypeptide is not a clostridial neurotoxin (holotoxin) molecule. | ||||||
| 2 | SUPPRESSION OF ITCH | US15964969 | 2018-04-27 | US20180298367A1 | 2018-10-18 | KEITH FOSTER |
| The invention provides a polypeptide, for use in suppressing or treating itch, wherein the polypeptide comprises: a non-cytotoxic protease, which protease is capable of cleaving a SNARE protein in an itch-specific DRG neuron or a pruriceptor; a Targeting Moiety (TM) that is capable of binding to a Binding Site on the itch-specific DRG neuron or a pruriceptor, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the itch-specific DRG neuron or a pruriceptor, and wherein said itch-specific DRG neuron or a pruriceptor expresses said SNARE protein; and a translocation domain that is capable of translocating the protease from within an endosome, across the endosomal membrane and into the cytosol of the itch-specific DRG neuron or a pruriceptor; with the proviso that the polypeptide is not a clostridial neurotoxin (holotoxin) molecule. | ||||||
| 3 | NEISSERIA MENINGITIDIS TRYPSIN-LIKE SERINE PROTEASE POLYPEPTIDES AND COMPOSITIONS THEREOF | US15534443 | 2015-12-08 | US20180125961A1 | 2018-05-10 | Nadège ARNAUD-BARBE; Geneviève RENAULD-MONGENIE; Bachra ROKBI |
| The present invention relates to novel polypeptides derived from Neisseria meningitidis proteins, in particular auto-transporters of the trypsin-like serine protease subclass, such as IgA1P, App and AusI, and their use in immunogenic compositions i.a., vaccine compositions for the prevention and/or treatment of meningococcal infections. In particular, it provides fragments of IgA1P, App and AusI and polypeptides comprising or consisting of these fragments and fusions thereof, which may be used in immunogenic compositions, for example vaccine compositions. | ||||||
| 4 | FUSION PROTEINS AND METHODS FOR TREATING, PREVENTING OR AMELIORATING PAIN | US15661433 | 2017-07-27 | US20170327810A1 | 2017-11-16 | Peter JAMES; Keith FOSTER; John CHADDOCK; Roger Kei AOKI; Lance STEWARD; Joseph FRANCIS |
| A single chain polypeptide fusion protein, comprising: a non-cytotoxic protease capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a galanin targeting moiety; a protease cleavage site at which site the fusion protein is cleavable by a protease; a translocation domain capable of translocating the protease from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent; a first spacer located between the non-cytotoxic protease and the protease cleavage site; and a second spacer located between the galanin targeting moiety and the translocation domain. | ||||||
| 5 | Non-cytotoxic protein conjugates | US13343892 | 2012-01-05 | US08603779B2 | 2013-12-10 | Keith Foster; John Chaddock; Charles Penn; Kei Roger Aoki; Joseph Francis; Lance Steward |
| The present invention is directed to non-cytotoxic protein conjugates for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell. The protein conjugates comprise: (i) a galanin Targeting Moiety (TM), wherein the TM is an agonist of a receptor present on a nociceptive sensory afferent cell, and wherein the receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell; (ii) a non-cytotoxic protease or a fragment thereof, wherein the protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of the nociceptive sensory afferent cell; and (iii) a Translocation Domain, wherein the Translocation Domain translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell. Nucleic acid sequences encoding the protein conjugates, methods of preparing same and uses thereof are is also described. | ||||||
| 6 | NON-CYTOTOXIC PROTEIN CONJUGATES | US13343892 | 2012-01-05 | US20120156186A1 | 2012-06-21 | Keith FOSTER; John CHADDOCK; Charles PENN; Kei Roger AOKI; Joseph FRANCIS; Lance STEWARD |
| The present invention is directed to non-cytotoxic protein conjugates for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell. The protein conjugates comprise: (i) a galanin Targeting Moiety (TM), wherein the TM is an agonist of a receptor present on a nociceptive sensory afferent cell, and wherein the receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell; (ii) a non-cytotoxic protease or a fragment thereof, wherein the protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of the nociceptive sensory afferent cell; and (iii) a Translocation Domain, wherein the Translocation Domain translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell. Nucleic acid sequences encoding the protein conjugates, methods of preparing same and uses thereof are is also described. | ||||||
| 7 | かゆみの抑制 | JP2016524895 | 2014-07-09 | JP2016528889A | 2016-09-23 | キース・フォスター |
| かゆみの抑制本発明は、かゆみの抑制又は治療に使用するためのポリペプチドを提供し、該ポリペプチドは次のものを含む:非細胞毒性プロテアーゼ、ここで、該プロテアーゼは、かゆみ特異的DRGニューロン又は掻痒受容体においてSNAREタンパク質を切断することができる;該かゆみ特異的DRGニューロン又は掻痒受容体上の結合部位に結合することのできる標的化部分(TM)、ここで、該結合部位は、該かゆみ特異的DRGニューロン又は掻痒受容体内にあるエンドソームに組み込まれるようにエンドサイトーシスを受けることができ、該かゆみ特異的DRGニューロン又は掻痒受容体は、該SNAREタンパク質を発現し;及びエンドソーム内からエンドソーム膜を横切って該かゆみ特異的DRGニューロン又は掻痒受容体の細胞質ゾルにプロテアーゼを転位することのできる転位ドメイン;ただし、該ポリペプチドは、クロストリジウム神経毒(ホロトキシン)分子ではないものとする。 | ||||||
| 8 | SUPPRESSION OF ITCH | EP14739923.2 | 2014-07-09 | EP3019241B1 | 2018-05-30 | FOSTER, Keith |
| The invention provides a polypeptide, for use in suppressing or treating itch, wherein the polypeptide comprises: a non-cytotoxic protease, which protease is capable of cleaving a SNARE protein in an itch-specific DRG neuron or a pruriceptor; a Targeting Moiety (TM) that is capable of binding to a Binding Site on the itch-specific DRG neuron or a pruriceptor, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the itch-specific DRG neuron or a pruriceptor, and wherein said itch-specific DRG neuron or a pruriceptor expresses said SNARE protein; and a translocation domain that is capable of translocating the protease from within an endosome, across the endosomal membrane and into the cytosol of the itch-specific DRG neuron or a pruriceptor; with the proviso that the polypeptide is not a clostridial neurotoxin (holotoxin) molecule. | ||||||
| 9 | 融合タンパク質および疼痛を治療、予防または緩和するための方法 | JP2015529117 | 2013-08-27 | JP2015528461A | 2015-09-28 | ジェイムズ，ピーター; フォスター，キース; チャドック，ジョン; ケイ アオキ，ロジャー; スチュワート，ランス; フランシス，ジョセフ |
| 侵害受容性感覚求心路の開口放出融合装置を構成しているタンパク質を切断することが可能な非細胞傷害性プロテアーゼ(例えばクロストリジウム神経毒のL鎖またはIgAプロテアーゼ); 侵害受容性感覚求心路のエンドソームに取り込まれるエンドサイトーシスを受けることが可能な侵害受容性感覚求心路の結合部位に結合することが可能なガラニンターゲティング部分(例えばGALR1、GALR2、またはGALR3受容体); 非細胞傷害性プロテアーゼとガラニンターゲティング部分の間に位置し、その部位で融合タンパク質がプロテアーゼによって切断されうるプロテアーゼ切断部位; エンドソームからエンドソーム膜を横断して、プロテアーゼを侵害受容性感覚求心路のサイトゾル内に転位置させることが可能なトランスロケーションドメイン(例えばクロストリジウム神経毒のHNドメイン); 非細胞傷害性プロテアーゼとプロテアーゼ切断部位の間に位置し、4〜25アミノ酸残基のアミノ酸配列を含んでいる第1のスペーサー; およびガラニンターゲティング部分とトランスロケーションドメインの間に位置し、4〜35アミノ酸残基のアミノ酸配列を含んでいる第2のスペーサーを含む、単鎖ポリペプチド融合タンパク質。このポリペプチド融合タンパク質をコードしている核酸配列、その調製方法およびその使用(例えば疼痛の治療、予防または緩和)についても記載する。【選択図】図3 | ||||||
| 10 | Drugs for bacterial meningitis | JP2000512567 | 1998-09-23 | JP2001517637A | 2001-10-09 | ハース ガービー; ローレンツェン ディルク; マイヤー トーマス; デュクス フランク |
| (57)【要約】 本発明は細菌性髄膜炎に対する新規薬剤に関する。 | ||||||
| 11 | FUSION PROTEINS AND METHODS FOR TREATING, PREVENTING OR AMELIORATING PAIN | EP13759562.5 | 2013-08-27 | EP2888359B1 | 2017-04-12 | JAMES, Peter; FOSTER, Keith; CHADDOCK, John; AOKI, Roger Kei; STEWARD, Lance; FRANCIS, Joseph |
| 12 | SUPPRESSION OF ITCH | EP14739923.2 | 2014-07-09 | EP3019241A1 | 2016-05-18 | FOSTER, Keith |
| The invention provides a polypeptide, for use in suppressing or treating itch, wherein the polypeptide comprises: a non-cytotoxic protease, which protease is capable of cleaving a SNARE protein in an itch-specific DRG neuron or a pruriceptor; a Targeting Moiety (TM) that is capable of binding to a Binding Site on the itch-specific DRG neuron or a pruriceptor, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the itch-specific DRG neuron or a pruriceptor, and wherein said itch-specific DRG neuron or a pruriceptor expresses said SNARE protein; and a translocation domain that is capable of translocating the protease from within an endosome, across the endosomal membrane and into the cytosol of the itch-specific DRG neuron or a pruriceptor; with the proviso that the polypeptide is not a clostridial neurotoxin (holotoxin) molecule. | ||||||
| 13 | FUSION PROTEINS AND METHODS FOR TREATING, PREVENTING OR AMELIORATING PAIN | EP13759562.5 | 2013-08-27 | EP2888359A1 | 2015-07-01 | JAMES, Peter; FOSTER, Keith; CHADDOCK, John; AOKI, Roger Kei; STEWARD, Lance; FRANCIS, Joseph |
| A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, which protease is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent (eg clostridial neurotoxin L-chain or IgA protease); a galanin Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent (eg GALR1, GALR2, or GALR3 receptor); a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease and the galanin Targeting Moiety; a translocation domain that is capable of translocating the protease from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent (eg HN domain of clostridial neurotoxin); a first spacer located between the non- cytotoxic protease and the protease cleavage site, wherein said first spacer comprises an amino acid sequence of from 4 to 25 amino acid residues; and a second spacer located between the galanin Targeting Moiety and the translocation domain, wherein said second spacer comprises an amino acid sequence of from 4 to 35 amino acid residues. Nucleic acid sequences encoding the polypeptide fusion proteins, methods of preparing same and uses thereof are also described (eg of treating, preventing or ameliorating pain). | ||||||
| 14 | FUSION PROTEINS AND METHODS FOR TREATING, PREVENTING OR AMELIORATING PAIN | EP17165621.8 | 2013-08-27 | EP3246405A1 | 2017-11-22 | JAMES, Peter; FOSTER, Keith; CHADDOCK, John; AOKI, Roger Kei; STEWARD, Lance; FRANCIS, Joseph |
A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, which protease is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent (eg clostridial neurotoxin L-chain or IgA protease); a galanin Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent (eg GALR1, GALR2, or GALR3 receptor); a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease and the galanin Targeting Moiety; a translocation domain that is capable of translocating the protease from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent (eg HN domain of clostridial neurotoxin); a first spacer located between the non- cytotoxic protease and the protease cleavage site, wherein said first spacer comprises an amino acid sequence of from 4 to 25 amino acid residues; and a second spacer located between the galanin Targeting Moiety and the translocation domain, wherein said second spacer comprises an amino acid sequence of from 4 to 35 amino acid residues. Nucleic acid sequences encoding the polypeptide fusion proteins, methods of preparing same and uses thereof are also described (eg of treating, preventing or ameliorating pain).
|
||||||
| 15 | NEISSERIA MENINGITIDIS TRYPSIN-LIKE SERINE PROTEASE POLYPEPTIDES AND COMPOSITIONS THEREOF | EP15807872.5 | 2015-12-08 | EP3230444A1 | 2017-10-18 | ARNAUD-BARBE, Nadège; RENAULD-MONGENIE, Geneviève; ROKBI, Bachra |
| The present invention relates to novel polypeptides derived from Neisseria meningitidis proteins, in particular auto-transporters of the trypsin-like serine protease subclass, such as IgA1P, App and AusI, and their use in immunogenic compositions i.a., vaccine compositions for the prevention and/or treatment of meningococcal infections. In particular, it provides fragments of IgA1P, App and AusI and polypeptides comprising or consisting of these fragments and fusions thereof, which may be used in immunogenic compositions, for example vaccine compositions. | ||||||
| 16 | MITTEL GEGEN BAKTERIELLE MENINGITIS | EP98952634.8 | 1998-09-23 | EP1015021A2 | 2000-07-05 | LORENZEN, Dirk; DÜX, Frank; MEYER, Thomas; HAAS, Gaby |
| The invention relates to novel agents for combating bacterial meningitis. | ||||||
| 17 | 통증을 치료, 예방 또는 개선하는 융합단백질 및 그의 제조방법 | KR1020157005061 | 2013-08-27 | KR1020150068353A | 2015-06-19 | 제임스,피터; 포스텔,키이스; 채독,존; 아키,로겔케이; 스튜어드,랜스; 프란치스코,조셉 |
| 구심성통각감각의세포외융합장치의단백질을절단할수 있는비-세포독성프로테아제; 구심성통각감각내에서엔도솜으로통합되는세포이물흡수를수행하는구심성통각감각의결합부위에결합가능한갈라닌표적화체; 비-세포독성프로테아제와갈라닌표적화체사이에위치한프로테아제에의해절단될수 있는융합단백질의프로테아제절단부위; 상기프로테아제를엔도솜내에서부터엔도솜막을통과하여구심성통각감각의세포질로전좌시킬수 있는전좌도메인; 비-세포독성프로테아제와프로테아제절단부위사이에위치한 4 내지 25 개의아미노산잔기의아미노산서열을포함하는제1 스페이서; 갈라닌표적화체와전좌도메인사이에위치한 4 내지 35 개의아미노산잔기의아미노산서열을포함하는제2 스페이서를포함하는단일사슬폴리펩티드융합단백질에관한것이다. 상기폴리펩티드융합단백질을코딩하는핵산서열, 그들의제조방법및 사용에대해서도설명된다. | ||||||
| 18 | 가려움증 억제 | KR1020167003023 | 2014-07-09 | KR1020160030392A | 2016-03-17 | 포스터,키이쓰 |
| 본발명은프로테아제가가려움증-특이 DRG 뉴런또는소양수용기중 SNARE 단백질을절단할수 있는것인, 비-세포독성프로테아제; 가려움증-특이 DRG 뉴런또는소양수용기상의결합부위에결합할수 있는표적화모이어티 (TM)로서, 결합부위는세포내이입을통해가려움증-특이 DRG 뉴런또는소양수용기내의엔도솜내로혼입될수 있고, 여기서상기가려움증-특이 DRG 뉴런또는소양수용기는상기 SNARE 단백질을발현하는것인표적화모이어티 (TM); 및프로테아제를엔도솜내부로부터엔도솜막을통과하여가려움증-특이 DRG 뉴런또는소양수용기의시토졸내로전위시킬수 있는전위도메인을포함하는폴리펩티드이되, 단, 폴리펩티드는클로스트리디움(clostridial) 신경독소 (홀로톡신) 분자가아닌것인, 가려움증억제또는치료에서사용하기위한폴리펩티드를제공한다. | ||||||
| 19 | AGENTS FOR COMBATING BACTERIAL MENINGITIS | PCT/EP9806069 | 1998-09-23 | WO9915198A3 | 1999-06-17 | LORENZEN DIRK; DUEX FRANK; MEYER THOMAS; HAAS GABY |
| The invention relates to novel agents for combating bacterial meningitis. | ||||||
QQ群二维码
意见反馈
意见反馈